BHVN Stock Price
BHVN RSI Chart
BHVN Valuation
BHVN Price/Sales (Trailing)
BHVN Profitability
BHVN Fundamentals
BHVN Revenue
BHVN Earnings
Price Action
Last 7 days
-9.7%
Last 30 days
2.1%
Last 90 days
-89.9%
Trailing 12 Months
-87.5%
BHVN Financial Health
BHVN Investor Care
Peers (Alternatives to Biohaven Pharmaceutical Holding Company)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
| MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
| SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Financials for Biohaven Pharmaceutical Holding Company
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
| Revenue | 16.6% | 859,684,000 | 737,538,000 | 462,509,000 | 307,610,000 | 189,534,000 |
| Gross Profit | 53.3% | 370,845,000 | 241,927,000 | 145,121,000 | - | - |
| Operating Expenses | 12.0% | 1,074,889,000 | 960,140,000 | 886,542,000 | - | - |
| S&GA Expenses | 10.3% | 861,667,000 | 781,269,000 | 713,549,000 | 616,478,000 | 571,500,000 |
| R&D Expenses | 37.8% | 514,380,000 | 373,328,000 | 361,340,000 | 343,662,000 | 315,042,000 |
| EBITDA | -38.2% | -853,666,000 | -617,866,000 | -786,098,000 | - | - |
| EBITDA Margin | -18.5% | -0.99 | -0.84 | -1.70 | - | - |
| Earnings Before Taxes | -34.8% | -909,405,000 | -674,413,000 | -843,323,000 | -856,069,000 | -874,182,000 |
| EBT Margin | -15.7% | -1.06 | -0.91 | -1.82 | - | - |
| Interest Expenses | 0.1% | 32,302,000 | 32,267,000 | 32,293,000 | 31,888,000 | 31,054,000 |
| Net Income | -33.0% | -929,781,000 | -699,055,000 | -846,586,000 | -866,039,000 | -889,412,000 |
| Net Income Margin | -14.2% | -1.08 | -0.95 | -1.83 | - | - |
| Free Cahsflow | 14.1% | -558,518,000 | -650,113,000 | -832,818,000 | - | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
| Assets | 1.1% | 1,386 | 1,372 | 1,077 | 1,131 | 846 |
| Current Assets | 0.3% | 1,174 | 1,171 | 876 | 944 | 667 |
| Cash Equivalents | 39.5% | 236 | 169 | 172 | 501 | 308 |
| Inventory | 16.7% | 107 | 91.00 | 81.00 | 75.00 | 64.00 |
| Net PPE | 8.2% | 16.00 | 15.00 | 15.00 | 10.00 | 11.00 |
| Liabilities | 19.2% | 2,192 | 1,838 | 1,760 | 1,662 | 1,242 |
| Current Liabilities | 16.6% | 672 | 576 | 534 | 462 | 399 |
| Long Term Debt | 20.6% | 765 | 634 | 627 | 619 | 274 |
| LT Debt, Current | NaN% | - | - | - | - | - |
| LT Debt, Non Current | 125.9% | 619 | 274 | - | - | - |
| Retained Earnings | -16.3% | -3,143 | -2,702 | -2,585 | -2,386 | -2,214 |
| Additional Paid-In Capital | 28.9% | 167 | 130 | 170 | 165 | 142 |
| Accumulated Depreciation | - | 5.00 | - | - | - | - |
| Shares Outstanding | 0.8% | 71.00 | 71.00 | 67.00 | 65.00 | 65.00 |
| Minority Interest | -12.1% | -4.62 | -4.13 | -3.63 | -3.23 | -2.72 |
| Float | - | 4,260 | - | - | - | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 |
| Cashflow From Operations | 14.3% | -556 | -649 | -831 | -849 | -809 |
| Share Based Compensation | 9.2% | 175 | 160 | 127 | 116 | 103 |
| Cashflow From Investing | 4.8% | -321 | -337 | 27.00 | 206 | -84.76 |
| Cashflow From Financing | 16.9% | 809 | 692 | 845 | 827 | 938 |
Risks for BHVN
What is the probability of a big loss on BHVN?
89.5%
Probability that Biohaven Pharmaceutical Holding Company stock will be more than 20% underwater in next one year
87.8%
Probability that Biohaven Pharmaceutical Holding Company stock will be more than 30% underwater in next one year.
53.4%
Probability that Biohaven Pharmaceutical Holding Company stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BHVN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Biohaven Pharmaceutical Holding Company was unfortunately bought at previous high price.
Drawdowns
Returns for BHVN
Cumulative Returns on BHVN
-10.8%
5-Year Cumulative Returns
-36.6%
3-Year Cumulative Returns
What are the long-term rolling returns for BHVN?
FIve years rolling returns for Biohaven Pharmaceutical Holding Company.
Annualized Returns
Which funds bought or sold BHVN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | sold off | -100 | -1,081,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | sold off | -100 | -3,000 | - | -% |
2023-02-28 | Voya Investment Management LLC | sold off | -100 | -3,666,000 | - | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | sold off | -100 | -408,000 | - | -% |
2023-02-17 | TRUIST FINANCIAL CORP | sold off | -100 | -324,000 | - | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | sold off | -100 | -7,000 | - | -% |
2023-02-15 | Utah Retirement Systems | sold off | -100 | -1,194,000 | - | -% |
2023-02-15 | JANE STREET GROUP, LLC | sold off | -100 | -4,644,000 | - | -% |
2023-02-15 | GAMCO INVESTORS, INC. ET AL | sold off | -100 | -4,134,000 | - | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | sold off | -100 | -47,530,000 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Biohaven Pharmaceutical Holding Company News
Schedule 13G FIlings of Biohaven Pharmaceutical Holding Company
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 10, 2022 | capital world investors | 4.9% | 3,446,156 | SC 13G/A | |
| Jun 10, 2022 | capital international investors | 2.2% | 1,569,985 | SC 13G/A | |
| May 10, 2022 | capital world investors | 10.0% | 7,075,514 | SC 13G/A | |
| Feb 11, 2022 | capital world investors | 9.4% | 6,178,009 | SC 13G/A | |
| Feb 11, 2022 | capital international investors | 7.8% | 5,104,501 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.1% | 4,635,280 | SC 13G/A | |
| Feb 17, 2021 | capital international investors | 10.1% | 6,053,468 | SC 13G/A | |
| Feb 16, 2021 | capital world investors | 7.8% | 4,649,448 | SC 13G | |
| Feb 02, 2021 | blackrock inc. | 5.9% | 3,524,951 | SC 13G | |
| Feb 14, 2020 | janus henderson group plc | 0.0% | 0 | SC 13G/A |
BHVN Fair Value
Latest Insider Trading transactions for BHVN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2022-10-03 | CHILDS JOHN W | back to issuer | -1,485,000 | 148 | -10,000 | - |
2022-10-03 | Coric Vlad | back to issuer | -13,669,400 | 148 | -92,050 | chief executive officer |
2022-10-03 | HUGIN ROBERT J | back to issuer | -430,650 | 148 | -2,900 | - |
2022-10-03 | Bailey Gregory | back to issuer | -383,674,000 | 148 | -2,583,660 | - |
2022-10-03 | Coric Vlad | back to issuer | -2,840,800 | 148 | -19,130 | chief executive officer |
2022-10-03 | Stock Elyse | back to issuer | -1,646,860 | 148 | -11,090 | chief medical officer |
2022-10-03 | Stock Elyse | back to issuer | -798,039 | 148 | -5,374 | chief medical officer |
2022-10-03 | Engelhart James | back to issuer | -2,361,150 | 148 | -15,900 | strategic advisor |
2022-10-03 | Conway Charles | back to issuer | -3,320,760 | 148 | -22,362 | chief scientific officer |
2022-10-03 | Tilton John | back to issuer | -239,679 | 148 | -1,614 | chief commercial officer |
About Biohaven Pharmaceutical Holding Company
Vladimir Coric
930
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
BHVN Income Statement
2022-03-31CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
|---|---|---|
Mar. 31, 2022 | Mar. 31, 2021 | |
| Revenues: | ||
| Total revenues | $ 318,852 | $ 43,823 |
| Operating expenses: | ||
| Cost of sales | 26,342 | 12,862 |
| Research and development expense | 119,099 | 107,111 |
| Selling, general and administrative | 227,243 | 159,523 |
| Total operating expenses | 372,684 | 279,496 |
| Loss from operations | (53,832) | (235,673) |
| Other income (expense): | ||
| Interest expense | (17,216) | (7,731) |
| Interest expense on mandatorily redeemable preferred shares | (7,917) | (7,943) |
| Interest expense on liability related to sale of future royalties | (17,314) | (13,508) |
| Change in fair value of derivatives | 3,604 | (210) |
| Gain from equity method investment | 0 | 5,261 |
| Other income (expense), net | 81 | (1,700) |
| Total other expense, net | (38,762) | (25,831) |
| Loss before provision for income taxes | (92,594) | (261,504) |
| Provision for income taxes | 24,303 | 3,824 |
| Net loss | (116,897) | (265,328) |
| Net loss attributable to non-controlling interests | 498 | 360 |
| Deemed dividend upon repurchase of preferred shares in consolidated subsidiary | (92,673) | 0 |
| Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. | $ (209,072) | $ (264,968) |
| Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - basic (in dollars per share) | $ (2.97) | $ (4.27) |
| Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - diluted (in dollars per share) | $ (2.97) | $ (4.27) |
| Weighted average common shares outstanding - basic (shares) | 70,332,274 | 62,040,715 |
| Weighted average common shares outstanding - diluted (shares) | 70,332,274 | 62,040,715 |
| Comprehensive loss: | ||
| Net loss | $ (116,897) | $ (265,328) |
| Other comprehensive (loss) income, net of tax | (2,325) | 95 |
| Comprehensive loss | (119,222) | (265,233) |
| Less: comprehensive loss attributable to non-controlling interests | 498 | 360 |
| Comprehensive loss attributable to Biohaven Pharmaceutical Holding Company Ltd. | (118,724) | (264,873) |
| Product revenue, net | ||
| Revenues: | ||
| Total revenues | 123,590 | 43,823 |
| Collaboration and other revenue | ||
| Revenues: | ||
| Total revenues | $ 195,262 | $ 0 |
BHVN Balance Sheet
2022-03-31CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 169,065 | $ 171,945 |
| Marketable securities | 433,410 | 192,648 |
| Trade receivable, net | 328,342 | 308,269 |
| Inventory | 91,281 | 80,608 |
| Prepaid expenses | 104,891 | 88,838 |
| Other current assets | 44,096 | 33,946 |
| Total current assets | 1,171,085 | 876,254 |
| Property and equipment, net | 14,534 | 14,690 |
| Intangible assets, net | 55,910 | 56,438 |
| Other assets | 130,188 | 129,830 |
| Total assets | 1,371,717 | 1,077,212 |
| Current liabilities: | ||
| Accounts payable | 56,202 | 51,683 |
| Accrued expenses and other current liabilities | 457,412 | 420,019 |
| Current portion of mandatorily redeemable preferred shares | 62,500 | 62,500 |
| Total current liabilities | 576,114 | 534,202 |
| Long-term debt | 634,106 | 626,720 |
| Liability related to sale of future royalties, net | 377,998 | 367,645 |
| Mandatorily redeemable preferred shares, net | 162,994 | 155,737 |
| Derivative liability | 9,120 | 13,110 |
| Obligation to perform R&D services | 36,016 | 50,571 |
| Other long-term liabilities | 41,782 | 12,236 |
| Total liabilities | 1,838,130 | 1,760,221 |
| Commitments and contingencies | ||
| Contingently redeemable non-controlling interests | 0 | 60,000 |
| Shareholders’ deficit: | ||
| Common shares, no par value; 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 70,540,802 and 66,933,531 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 2,112,686 | 1,676,792 |
| Additional paid-in capital | 129,580 | 169,656 |
| Accumulated other comprehensive loss | (2,398) | (73) |
| Accumulated deficit | (2,702,154) | (2,585,755) |
| Total shareholders’ deficit attributable to Biohaven Pharmaceutical Holding Company Ltd. | (462,286) | (739,380) |
| Non-controlling interests in consolidated subsidiaries | (4,127) | (3,629) |
| Total shareholders' deficit | (466,413) | (743,009) |
| Total liabilities and shareholders’ deficit | $ 1,371,717 | $ 1,077,212 |